4.8 Article

Latency-Associated Degradation of the MRP1 Drug Transporter During Latent Human Cytomegalovirus Infection

期刊

SCIENCE
卷 340, 期 6129, 页码 199-202

出版社

AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/science.1235047

关键词

-

资金

  1. Cambridge Institute for Medical Research
  2. Wellcome Trust [093966/Z/10/Z, 084957/Z/08/Z]
  3. Agency for Science, Technology and Research, Singapore
  4. MRC [G0701279]
  5. NIHR Cambridge Biomedical Research Centre
  6. Medical Research Council [G0701279, MR/K021087/1] Funding Source: researchfish
  7. MRC [MR/K021087/1, G0701279] Funding Source: UKRI
  8. Wellcome Trust [084957/Z/08/Z, 093966/Z/10/Z] Funding Source: Wellcome Trust

向作者/读者索取更多资源

The reactivation of latent human cytomegalovirus (HCMV) infection after transplantation is associated with high morbidity and mortality. In vivo, myeloid cells and their progenitors are an important site of HCMV latency, whose establishment and/or maintenance require expression of the viral transcript UL138. Using stable isotope labeling by amino acids in cell culture-based mass spectrometry, we found a dramatic UL138-mediated loss of cell surface multidrug resistance-associated protein-1 (MRP1) and the reduction of substrate export by this transporter. Latency-associated loss of MRP1 and accumulation of the cytotoxic drug vincristine, an MRP1 substrate, depleted virus from naturally latent CD14(+) and CD34(+) progenitors, all of which are in vivo sites of latency. The UL138-mediated loss of MRP1 provides a marker for detecting latent HCMV infection and a therapeutic target for eliminating latently infected cells before transplantation.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据